Cigna Doubles Down on Biosimilar Incentives

Cigna Corp. — which made headlines earlier this year when it indicated patients could receive a monetary award if they switch from a high-priced psoriasis drug to a cheaper biologic — now appears to be making that strategy an official program, starting with a different drug.

In a recent press release, the insurer revealed that starting in July, two approved biosimilars for Janssen’s immunosuppressive drug Remicade (infliximab) — Avsola and Inflectra — will move to preferred status on its formularies. “With these updates, Cigna is taking concrete steps to help patients and plans realize the promise of alternative, clinically effective treatment options,” the company said.

More specifically, Cigna “will offer all eligible customers the option to receive a one-time $500 debit card for health care services and products if they decide to switch to a biosimilar or another preferred medication.”

Cigna’s new “Shared Savings Program” comes months after the American Journal of Managed Care obtained a letter sent to providers by the insurer in March, stating that patients could receive a $500 debit card if they switch from Novartis’ Cosentyx (secukinumab) to Eli Lilly & Co.’s Taltz (ixekizumab) or an older biologic before Aug. 31 and then refill the prescription before Dec. 31.

At the time, Taltz was already preferred over Cosentyx on most of Cigna’s 2021 formularies, “so the $500 card program may have been a signal that Cigna didn’t feel that their traditional utilization management tools (e.g. tier placement, prior authorization, step throughs) were as effective at migrating existing patients to a preferred drug when it comes to these chronic drugs,” says Omar Hafez, managing director at Avalere Health.

According to Hafez, patient preferences as well as “continuity of care/non-medical switching/step therapy laws” are all barriers to moving patients from their existing biologics, “but the $500 card could help convince some patients to switch on their own, partially neutralizing these barriers.”

In Hafez’s view, it’s notable that the insurer is now rolling out a more official policy that targets drugs other than Cosentyx and Taltz.

“The fact that Cigna is rolling this out to the infliximabs could be a sign that Cigna was pleased with the results of that program and is trying to replicate it in a physician administered drug setting,” he says.

In addition, “what is interesting is that Cigna indicated that it has two preferred biosimilars for infliximab, not all three that are available,” Hafez adds. “This signals that Cigna wants to play a role in managing the formulary and that within biosimilars there can be winners and losers.”

Learn more about MMIT’s Analytics solution to understand market access and payer coverage.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Related Posts

icons
May 16

Balancing Technology, Human Touch Can Improve Therapy Access, Adherence

Read More
blood-test
May 16

FDA Approves Second Gene Therapy, but Will Price Prove to Be Too High?

Read More
walgreens
May 16

Walgreens Will Launch New Specialty Pharmacy With ‘Significant’ Cell and Gene Therapy Offering

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today